Auswahl der wissenschaftlichen Literatur zum Thema „Complication thrombotique“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Complication thrombotique" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Complication thrombotique"
MÉRIC, M., M. HOUBERDON und P. LAFOURCADE. „Thrombose veineuse d’effort du membre inférieur: une pathologie du sport à ne pas méconnaître“. Revue Médecine et Armées, Volume 43, Numéro 5 (01.12.2015): 479–83. http://dx.doi.org/10.17184/eac.6930.
Der volle Inhalt der QuelleGorgi, K., F. Toulali, F. Kamel, K. Rifai, H. Iraqi und M. E. H. Gharbi. „Complication thrombotique chez le diabétique en cétoacidose : à propos d’un cas“. Annales d'Endocrinologie 82, Nr. 5 (Oktober 2021): 487. http://dx.doi.org/10.1016/j.ando.2021.08.681.
Der volle Inhalt der QuelleGuanella, Raphaël. „Syndrome post-thrombotique : la complication négligée de la maladie thromboembolique veineuse“. Revue Médicale Suisse 9, Nr. 372 (2013): 321–25. http://dx.doi.org/10.53738/revmed.2013.9.372.0321.
Der volle Inhalt der QuelleFarah, R., M. Lambert, A. L. Fauchais, V. Queyrel, U. Michon-Pasturel, M. Hebbar, E. Hachulla, P. Y. Hatron und B. Devulder. „Syndrome de Gougerot-Sjögren et purpura thrombotique thrombocytopénique, une complication exceptionnelle : à propos d'un cas“. La Revue de Médecine Interne 22 (Dezember 2001): 538s. http://dx.doi.org/10.1016/s0248-8663(01)80244-7.
Der volle Inhalt der QuelleMerdji, Hamid, Laurent Sattler, Sibylle Cunat, Ferhat Meziani und Julie Helms. „Hémostase et COVID-19“. Médecine Intensive Réanimation 30, Hors-série 1 (16.06.2021): 35–42. http://dx.doi.org/10.37051/mir-00062.
Der volle Inhalt der QuelleMasmoudi, W., E. Ezine, L. Adelmand, S. Chantepie und L. Verneuil. „La microangiopathie thrombotique (MAT) : une complication à rechercher dans les lymphomes T épidermotropes traités par gemcitabine“. Annales de Dermatologie et de Vénéréologie 144, Nr. 12 (Dezember 2017): S277. http://dx.doi.org/10.1016/j.annder.2017.09.456.
Der volle Inhalt der QuelleMutchmore, Alexandre, Dominique Toupin, Geneviève Le Templier und Bobby Gouin. „Bilateral Asynchronous Adrenal Infarction in JAK2-Positive Essential Thrombocythemia“. Canadian Journal of General Internal Medicine 18, Nr. 1 (25.03.2023): 66–70. http://dx.doi.org/10.22374/cjgim.v18i1.667.
Der volle Inhalt der QuelleTejpal, Ambika, Peter Economopoulos, Roseann Andreou und James Stevenson. „Vaccine-Induced Immune Thrombotic Thrombocytopenia after Receiving the ChAdOx1 nCoV-19 Vaccine“. Canadian Journal of General Internal Medicine 16, Nr. 2 (21.06.2021): 34–37. http://dx.doi.org/10.22374/cjgim.v16i2.559.
Der volle Inhalt der QuelleNou-Howaldt, M., V. Monnin-Bares, J. P. Laroche, C. Calais, A. Blouet, P. Lhorte und I. Quéré. „Une complication inhabituelle postangioplastie veineuse dans le cadre de la prise en charge d’un syndrome post-thrombotique : l’endothélialisation intrastent, à propos d’un cas clinique“. JMV-Journal de Médecine Vasculaire 43, Nr. 2 (März 2018): 126–27. http://dx.doi.org/10.1016/j.jdmv.2017.12.116.
Der volle Inhalt der QuelleDarnige, L., und A. Lillo-Le Louët. „Traitements par immunoglobulines et complications thrombotiques“. La Revue de Médecine Interne 35, Nr. 1 (Januar 2014): 39–44. http://dx.doi.org/10.1016/j.revmed.2013.07.006.
Der volle Inhalt der QuelleDissertationen zum Thema "Complication thrombotique"
Gourvil, Lemoigne Emmanuelle. „Place de l'infection à VIH dans la microangiopathie thrombotique : à propos d'un cas de microangiopathie thrombotique révélateur d'une infection à VIH“. Bordeaux 2, 1993. http://www.theses.fr/1993BOR23103.
Der volle Inhalt der QuelleMallol, Carola. „Syndrome des anticorps antiphospholipides : place des anticorps antiphosphatidylsérine dans les complications thrombotiques“. Montpellier 1, 2000. http://www.theses.fr/2000MON11140.
Der volle Inhalt der QuelleGautier, Éric. „Les micro-angiopathies thrombotiques chez la femme enceinte“. Bordeaux 2, 1990. http://www.theses.fr/1990BOR25159.
Der volle Inhalt der QuelleJavorschi, Sandrine. „Evolution de l'hémostase avec l'âge : effet de la pathologie thrombotique et résistance à la protéine C activée“. Bordeaux 2, 1996. http://www.theses.fr/1996BOR2P053.
Der volle Inhalt der QuelleChauleur, Céline. „Identification des facteurs de risque pour prévenir les complications thrombotiques et hémorragiques de la grossesse“. Saint-Etienne, 2009. http://www.theses.fr/2009STET003T.
Der volle Inhalt der QuelleKalawon, Ramesh. „Traitement de la maladie post-thrombotique fémorale par transposition saphéno-poplitée : à propos de 9 cas“. Bordeaux 2, 1995. http://www.theses.fr/1995BOR2M169.
Der volle Inhalt der QuelleMoussa, Mouhamed Djahoum. „Déterminants cliniques, physiopathologiques et pronostics associés aux complications liées à l’hémostase au cours des assistances circulatoires de courte durée à pompe centrifuge“. Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS055.
Der volle Inhalt der QuelleThe purpose of this dissertation is to characterize hemostasis-related complications in patients supported by peripheral VA-ECMO to improve their prevention and to optimize the antithrombotic therapeutic approaches in use. In a first study, we qualitatively and quantitatively described the composition of thrombi collected from the VA-ECMO circuits. We observed that these thrombi are mainly made of VWF, fibrin and in a lesser proportion of platelets and RBCs. Our quantitative approach also allowed us to demonstrate the presence of NETs while there was no active septic, confirming the possibility of aseptic NETosis under VA-ECMO. By hierarchical cluster analysis, we identified 2 types of thrombi, each of which may be related to a different mechanism of formation. In this study, the location of thrombi on the VA-ECMO circuit did not impact their compositions, highlighting the heterogeneity of thrombi formed within VA-ECMO and the multifactorial mechanisms that support thrombosis in this setting. In a second study, we compared the performance of surface coatings on VA-ECMO circuits to reduce thrombinoformation and its clinical consequences. Two of the most used coatings in daily practice were compared: the phosphorylcholin-based coating and the polysaccharide-albumin-based coating. We observed a higher rate of thrombotic complications in the phosphorylcholin group without any excess bleeding events or mortality in either group. In addition, compared with thrombi from phosphorylcholin-coated circuit junctions, those from polysaccharide-albumin-coated circuits were poorer in VWF. Our work suggests that the level of anticoagulation should be modulated according to the type of coating of the ECMO circuit.The aim of our third study was to identify the most relevant bleeding events that may guide clinical decision-making for more aggressive clinical management and a greater investment in research. To this end, we compared the association between 3 bleeding classifications with 28-day mortality. The ELSO definition already in use and the BARC classification classes ≥ type 2 were associated with 28-day mortality and thus retained as definitions of major bleeding. Laboratory parameters that are predictors major bleeding according to the ELSO definition were decreased fibrinogen, platelet count, and hemoglobin at cannulations. Body mass index and postcardiotomy etiology were also predictive of ELSO major bleeding. In an additional work related to the topic of the thesis, we studied two of the most used laboratory tests for the monitoring of systemic heparin during VA-ECMO, the APTT and the Anti-Xa activity, to identify the most relevant. First, we studied the relationship between these two tests and then analyzed in a second objective the impact of biological influencing factors on this relationship. Next, we determined their associations with thrombotic and hemorrhagic complications. Although linearly associated, the rate of discordance between their measurements was 39 % for an Anti-Xa reference range of 0.3 - 0.7 IU/mL. Neither APTT nor Anti-Xa was associated with thrombotic or bleeding complications. Taken together, our results highlight the heterogeneity of thrombi from peripheral VA-ECMO, the involvement of numerous causal factors that underline thrombotic and hemorrhagic complications, both not predictable by routine tests. Finally, our work underscored the need for new approaches in thrombotic or hemorrhagic complications management with targets set at an individual level considering both patient and ECMO circuit characteristics
Moustey, Francois. „Le syndrome catastrophique des antiphospholipides : état actuel des connaissances. Expérience personnelle : à propos d'un cas“. Bordeaux 2, 2001. http://www.theses.fr/2001BOR2M042.
Der volle Inhalt der QuellePoline, Diane. „Apport de l'échocardiographie transœsophagienne dans le choix du traitement des thromboses de prothèse valvulaire cardiaque : à propos de 69 épisodes thrombotiques“. Bordeaux 2, 1994. http://www.theses.fr/1994BOR23017.
Der volle Inhalt der QuelleDandachli, Mourad. „L’efficacité du CD154 monomérique dans le traitement des complications thrombotiques“. Thèse, 2016. http://hdl.handle.net/1866/19251.
Der volle Inhalt der QuelleCD154 has emerged as an important player in the pathogenesis of several autoimmune diseases, as well as vascular dysfunctions. CD154 is a member of the tumour necrosis factor family of pivotal importance in humoral immunity. However, CD154 also shares critical inflammatory functions through its interaction with its classical CD40 receptor or recently identified binding partners, namely αIIbβ3, α5β1 and αMβ2. These responses imply CD154 as a key factor in chronic inflammatory disorders including autoimmune diseases and thrombosis. Disrupting the interaction of CD154 with its receptors through anti-CD154 Abs significantly inhibits the development of these diseases, albeit serious side effects have been associated with these therapies. To overcome these adverse effects, other approaches such as knockout, antisense oligonucleotide and siRNA targeting were developed. These approaches were focused on the CD154/CD40 interaction and did not address the interaction of CD154 with its other receptors. Thus, there is a need for novel CD154 treatments for the prevention/abrogation of inflammatory or autoimmune diseases that address all CD154 receptors. Our group profoundly investigated the structural/functional interaction of CD154 with its various receptors. Given the importance of the trimeric structure of CD154 for its biological activity, we generated monomeric form of the molecule that can specifically bind to one receptor without inducing intracellular activation. This agent represents a potential therapeutic tool for the treatment of CD154-mediated diseases such as thrombotic events.